Pfizer Inc. $PFE Shares Acquired by Fort Washington Investment Advisors Inc. OH

Key Points

• Fort Washington Investment Advisors increased its stake in Pfizer by 11.2%, adding 190,946 shares to own 1,892,663 shares valued at about $48.23 million per its latest SEC filing.
• Pfizer announced a quarterly dividend of $0.43 per share (annualized $1.72) with an ex‑dividend/record date of Jan. 23 and pay date Mar. 6, implying a ~6.9% yield and a stated payout ratio of 100%.
• Pfizer reported Q results of $0.87 EPS (beating the $0.79 estimate) on $16.65B revenue (slightly below estimates), set FY2025 guidance of $3.00–$3.15 EPS, and carries a Wall Street consensus of "Hold" with an average target around $28.06.

Fort Washington Investment Advisors Inc. OH increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 11.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,892,663 shares of the biopharmaceutical company's stock after acquiring an additional 190,946 shares during the period. Fort Washington Investment Advisors Inc. OH's holdings in Pfizer were worth $48,225,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Curio Wealth LLC increased its holdings in shares of Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 1,098 shares in the last quarter. Bayforest Capital Ltd purchased a new stake in Pfizer during the first quarter worth about $28,000. Harbor Asset Planning Inc. acquired a new position in Pfizer during the second quarter worth about $29,000. Howard Hughes Medical Institute acquired a new position in Pfizer during the second quarter worth about $30,000. Finally, Darwin Wealth Management LLC purchased a new position in Pfizer in the second quarter valued at about $32,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Trading Down 0.4%

Shares of NYSE PFE opened at $24.99 on Tuesday. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The stock's 50 day moving average price is $25.16 and its two-hundred day moving average price is $24.89. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69. The stock has a market capitalization of $142.07 billion, a P/E ratio of 14.53 and a beta of 0.46.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer's payout ratio is presently 100.00%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on PFE. Citigroup initiated coverage on Pfizer in a research note on Tuesday, December 2nd. They set a "neutral" rating and a $26.00 price target on the stock. HSBC reaffirmed a "buy" rating and set a $29.00 price objective on shares of Pfizer in a report on Wednesday, December 10th. UBS Group reissued a "neutral" rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Morgan Stanley cut their price target on Pfizer from $32.00 to $28.00 and set an "equal weight" rating for the company in a research note on Friday, December 12th. Finally, BMO Capital Markets reiterated an "outperform" rating on shares of Pfizer in a research report on Wednesday, December 10th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $28.06.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.